CN112843133A - Traditional Chinese medicine composition for treating cerebral infarction and preparation method thereof - Google Patents
Traditional Chinese medicine composition for treating cerebral infarction and preparation method thereof Download PDFInfo
- Publication number
- CN112843133A CN112843133A CN202110242613.6A CN202110242613A CN112843133A CN 112843133 A CN112843133 A CN 112843133A CN 202110242613 A CN202110242613 A CN 202110242613A CN 112843133 A CN112843133 A CN 112843133A
- Authority
- CN
- China
- Prior art keywords
- traditional chinese
- chinese medicine
- cerebral infarction
- medicine composition
- treating cerebral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/238—Saposhnikovia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of pharmaceutical preparations, and discloses a traditional Chinese medicine composition for treating cerebral infarction and a preparation method thereof. The invention screens out the optimal compatibility proportion of the three traditional Chinese medicines as 10: 3: 2. the invention is based on holism concept, exerts the advantages of syndrome differentiation and treatment of traditional Chinese medicine, selects pure natural medicines for compatibility, and has the effects of activating blood and stimulating the menstrual flow, and dissipating blood stasis and dredging collaterals. In addition, animal experiments show that the invention can reduce the volume of cerebral infarction, reduce the expression level of IL-1 beta, TNF-alpha and MMP-9 in serum and obviously improve the nerve function. The traditional Chinese medicine composition provided by the invention can be used for preparing a medicine for preventing and treating cerebral infarction with good curative effect, safety and reliability.
Description
Technical Field
The invention relates to the field of medicines, and in particular relates to a traditional Chinese medicine composition for treating cerebral infarction and a preparation method thereof
Background
Background
Cerebral infarction, called apoplexy and stroke in traditional Chinese medicine, accounts for a higher proportion of cerebrovascular diseases, about 69.6-70.8%, can occur in any age group, is often seen in middle-aged and old people of 45-70 years old, has a relatively urgent disease incidence and extremely high disability rate and disease death rate, and is the leading cause of death in China. With the improvement of the living standard of people, the incidence rate of cerebral infarction is continuously increased, and patients with cerebral infarction can lose partial or incomplete mobility, thereby bringing heavy burden to individuals, families and society. Therefore, effective drugs for preventing and treating cerebral infarction are urgently needed to be found so as to relieve the progress of cerebral infarction and aggravation of cerebral infarction. In recent years, the unique advantages of the Chinese herbal compound preparation, namely 'multi-component-multi-target-multi-way' become the focus of attention, and the research on the aspect of cerebrovascular diseases has been advanced to a certain extent
The traditional Chinese medicine considers that the internal basis of the stroke is deficiency, pathogenic factors are wind-fire phlegm stasis, and the obstruction of cerebral vessels directly causes the loss of vitality, hemiplegia and the like. The therapeutic principles of doctors of the past generations on apoplexy are mainly to open up spirit and induce resuscitation, dispel wind and dredge collaterals, activate blood and resolve phlegm, etc. The invention is prepared by matching and combining astragalus, red paeony root and divaricate saposhnikovia root, wherein the astragalus tonifies qi and raises yang, the red paeony root cools blood and removes stasis, and the divaricate saposhnikovia root dispels wind and relieves pain. The astragalus root is a monarch drug, greatly supplements primordial qi, nourishes brain collaterals, the red paeony root is a ministerial drug, promotes blood circulation, removes blood stasis, clears and activates the channels and collaterals, the divaricate saposhnikovia root is an assistant drug, gently rises and disperses, and the medicines are carried to reach brain orifices and nourish brain mansion.
Specifically, the Chinese medicinal composition of the invention is introduced as follows:
the astragalus is a traditional qi-tonifying traditional Chinese medicine, and recent researches show that the astragalus has the effects of inhibiting the activity of xanthine oxidase, eliminating free radicals, improving the activities of superoxide dismutase and peroxidase, improving the blood rheological property of patients with coronary heart disease, inhibiting the aggregation of platelets, enhancing myocardial contractility and the like. In addition, astragalus can tonify qi, strengthen body resistance and promote blood circulation, and has the important functions of enhancing capillary resistance, improving disease resistance, stimulating the central nervous system and prolonging the life of in vitro cells, which are all beneficial to relieving cerebral ischemic injury.
Red peony root, bitter in taste and slightly cold in nature, 263 patients with acute cerebral thrombosis are treated by students with modified medicine of lipid for promoting blood circulation (i.e. propyl gallate) with the original components, the effective rate reaches 92.01%, and researches show that the pharmaceutical composition has the effects of increasing cerebral blood flow, reducing cerebrovascular resistance, inhibiting platelet aggregation, inhibiting the function of internal coagulation, promoting fibrinolytic activity, reducing blood viscosity and the like, so that the pharmaceutical composition can improve cerebral metabolism, increase cerebral function, improve cerebral blood flow supply in a penumbra area, and reduce an infarction focus.
Ledebouriella root, a root of Ledebouriella root of Umbelliferae, is pungent and sweet in flavor and slightly warm in nature, and is a liver meridian wind-treating drug, which is said in Ben Cao Jing Shu (materia Medica) to be universal in treating wind, growing hair and dispersing energy. Modern researches have proved that radix Saposhnikoviae has antipyretic, analgesic, antiinflammatory, anticoagulant, antithrombotic, and immunity regulating effects.
Disclosure of Invention
The invention aims to solve the technical problem of providing a traditional Chinese medicine composition for treating cerebral infarction and a preparation method thereof.
In order to solve the technical problems, the technical scheme adopted by the invention is as follows:
disclosure of Invention
The invention aims to provide a traditional Chinese medicine composition for treating cerebral infarction and a preparation method thereof.
The purpose of the invention is realized by the following technical scheme:
a traditional Chinese medicine composition for treating cerebral infarction and a preparation method thereof are provided, the preparation method of the traditional Chinese medicine composition for treating cerebral infarction comprises the following steps:
step one, mixing the traditional Chinese medicine raw materials (astragalus, red peony root and divaricate saposhnikovia root) and distilled water according to a weight ratio of 1: 6-12 mixing and soaking;
step two, decocting the soaked astragalus, red peony root and divaricate saposhnikovia root, boiling for 1-2 hours, filtering to obtain filter residues, adding water for mixing, boiling, and repeating for 2-3 times;
and step three, combining the filtrates obtained each time, concentrating by using a rotary evaporator, and drying under reduced pressure and vacuum to obtain the traditional Chinese medicine composition for treating cerebral infarction.
After being matched with pharmaceutically acceptable auxiliary materials, the traditional Chinese medicine composition is prepared into a proper dosage form according to the conventional preparation method in the field. The Chinese medicinal composition can be oral liquid, tablet, capsule, and pill, preferably capsule and tablet.
According to the dosage of 'Chinese pharmacopoeia' 2020 edition, crude drug dosage X1 (astragalus root) 9-30g/kg, X2 (red peony root) 6-12g/kg and X3 (divaricate saposhnikovia root) 5-10g/kg are taken as dosage ranges, a longa modified wire-embolism method is adopted to prepare a cerebral infarction model rat, the nerve function is determined through nerve function grading, the cerebral infarction area is determined through a TTC dyeing method, the inflammation level is determined through the contents of IL-1 beta, TNF-alpha and MMP-9 in serum, and the method is used for systematically and deeply researching the effect of the compatibility of the traditional Chinese medicine components for treating the cerebral infarction.
The invention takes astragalus, red peony root and ledebouriella root as 3 factors for investigation, designs 6 dosage levels according to a uniform design table, and designs U6 (6) according to the uniform design table4) Experiments are carried out, and the optimal compatibility proportion of the astragalus, the red paeony root and the divaricate saposhnikovia root is determined by adopting a TTC staining method and an ELISA method and taking the nerve function score, the cerebral infarction area and the expression levels of IL-1 beta, TNF-alpha and MMP-9 in serum as investigation indexes.
The traditional Chinese medicine composition for treating cerebral infarction and the preparation method thereof provided by the invention have the advantages of simple operation, low cost, small toxic and side effects, stable chemical components and easier quality control in the production process.
In addition, the invention also provides a medicine prepared by the extraction process.
The invention takes water as solvent to determine the extraction process, and is environment-friendly and safe. And the effective components are extracted to the maximum extent by concentration of a rotary evaporator and vacuum drying extraction under reduced pressure, so that the loss of the effective components is avoided, and the production efficiency is improved. Pharmacological research results show that the traditional Chinese medicine composition prepared by the extraction process provided by the invention can obviously reduce the volume of cerebral infarction, reduce the expression levels of IL-1 beta, TNF-alpha and MMP-9 in serum, improve the nerve function, and has the effects of resisting inflammation, resisting thrombus and promoting angiogenesis.
Detailed Description
The invention discloses a traditional Chinese medicine composition for treating cerebral infarction and a preparation method thereof, and a person skilled in the art can use the contents for reference and appropriately improve process parameters to realize the purpose. It is expressly intended that all such similar substitutes and modifications which would be obvious to one skilled in the art are deemed to be included in the invention. While the present invention has been described in terms of preferred embodiments, it will be apparent to those skilled in the art that the present technology can be practiced and applied by modifying or appropriately combining the methods and applications described herein without departing from the spirit and scope of the invention.
Drugs and reagents used in the following examples:
astragalus root: inner Mongolia of origin, Heilongjiang Xiikang pharmaceutical Co., Ltd, lot number 20190501;
red peony root: liaoning, Heilongjiang Xiixiang pharmaceutical Co., Ltd., Lot 20190301;
wind prevention: inner Mongolia of origin, Heilongjiang Xiikang pharmaceutical Co., Ltd, lot number 20190402;
nimodipine tablets: tianjin Central pharmaceutical industry Co., Ltd, Specification: 20 mg/tablet, lot number 200605;
2% TTC staining solution: beijing Soilebao science and technology Co., Ltd., batch No. 20201029;
interleukin-1 beta (IL-1 beta); tumor necrosis factor (TNF- α); the matrix metalloproteinase-9 (MMP-9) content determination kits are all purchased from Nanjing institute of bioengineering, and have the batch number of 20201124
Examples the apparatus used:
m200pro plate reader (Tecan, Switzerland); SY500 rotary evaporator (shanghai yanglong biochemical instrument factory); ALPHA1-4/LD-plus freeze dryer (christ, Germany); KDC-160HR high speed refrigerated centrifuge (Kyoho, K.K., Innovation Co., Ltd.); AL204 electronic balance (Mettler-Torledo instruments Co., Ltd.)
The medicine and the raw materials and reagents used in the extraction process of the medicine provided by the invention can be purchased from the market.
Example 1 radix astragali-Chifeng decoction component compatibility design based on uniform design
According to the uniform test design method U6 (6)4) The proportion of the components is optimized, the six traditional Chinese medicines in the prescription are used as investigation factors, X1, X2 and X3 respectively represent three traditional Chinese medicines (namely three factors) in the traditional Chinese medicine compound, each factor is provided with 6 dosage levels, the experimental design is shown in table 1, and the total number of the three traditional Chinese medicines is 6.
Table 1 based on U6 · (6)4) The design table for optimizing and uniformly matching different components of the Chinese herbal compound
Referring to the dosage knot of 'Chinese pharmacopoeia' 2020 edition, crude drug dosage X1 (radix astragali) 9-30g/kg, X2 (radix Paeoniae Rubra) 6-12g/kg, and X3 (radix Saposhnikoviae) 5-10g/kg are used as dosage ranges, and the dosage ranges are divided into 6 dosage levels on average. The factors and levels are arranged according to a uniform design table, and the composition design is carried out, wherein each action has one composition, and the total number of the compositions is 6.
Table 2 is based on U6 [ (6 ]4) The design scheme for optimizing and uniformly mixing different components of the Chinese herbal compound
Example 2 determination of pharmacodynamic index of Astragalus root Chifeng decoction on cerebral infarction model rat
1 laboratory animal
SPF grade, male, SD rat, body weight (220 + -20) g, purchased from Experimental animals center of university of traditional Chinese medicine, Heilongjiang, license number SCXK (Black) 2013-. The animal of the study is approved by animal ethics committee of the university of traditional Chinese medicine of Heilongjiang under the approval number of 2017042005.
2 method
2.1 model preparation
The rat cerebral infarction model adopts a modified Longa line embolism method. The rats in each group are fasted before operation for over 12 hours without water supply, anesthetized by 10% chloral hydrate, depilated on the neck, the skin is cut along the middle of the neck, muscle tissue is separated in a blunt manner, and the right Common Carotid Artery (CCA), the External Carotid Artery (ECA) and the Internal Carotid Artery (ICA) are dissociated; the ECA and CCA are ligated by an operation line at the proximal end, and the ICA is clamped and closed by an artery clamp at the same time, so that a Y-shaped closed blood vessel environment is formed; cutting a small opening at the distal end of the CCA by using an ophthalmic scissors, inserting a nylon plug wire into the CCA along an incision, entering the ICA to the position of an artery clamp along the direction of a blood vessel, tying a slipknot above the opening, fixing the nylon plug wire, preventing bleeding after loosening the artery clamp, loosening the ICA artery clamp, slowly inserting the plug wire along the blood vessel until a slight resistance force is reached, stopping inserting (about 19-20mm at the bifurcation of the artery), fastening the slipknot, and suturing the skin. The sham group treatment was as above, but no ligation was performed.
2.2 neurological function assessment
Evaluation of nerve function: rats were evaluated for neurological function in each group at 1d, 7d, 14d post-model according to the modified Longa scoring criteria. The specific scoring criteria are as follows:
rat neurological function scoring standard
Note: rats scored 0 and 4 are model preparation failures
2.4 cerebral infarction volume detection
On the 14 th day after operation, rats are anesthetized with 10% chloral hydrate in the abdominal cavity, the chest cavity is opened after the sternum is cut off along the xiphoid process, the heart is exposed, a syringe needle is inserted into the apex of the heart to the root of the aorta, the left ventricle to the aorta is perfused with physiological saline at 37 ℃ rapidly after the infusion apparatus is connected, and then the right auricle is cut off to allow the perfusate to flow out. After 50ml of physiological saline is rapidly infused from the left ventricle, the lips, the limbs and the internal organs of the rat become white, the limbs become rigid, and then the head is rapidly cut off to take out the brain. Quickly freezing brain tissue in-20 deg.C refrigerator for 15min, cutting olfactory bulb, brainstem and cerebellum, and cutting the cerebrum into 5 coronal slices with thickness of about 2mm from front to back. The brain slices are placed in 2% TTC phosphate buffer solution, placed in a slice box and dyed in a constant temperature box at 37 ℃ for 20min in a dark place. During the period, the brain tissue section is turned over by forceps to ensure uniform staining. The TTC solution was aspirated off, 4% paraformaldehyde was added for fixation for 30min, and the normal tissue was red and the infarcted tissue was white, and photographed. The captured images were analyzed using Image Pro Plus 6.0 software. Calculating the infarct focus volume according to the formula V ═ t (A1+ A2 … … + An)/whole brain volume, and further calculating the percentage of the infarct focus volume in the whole brain volume, namely the cerebral infarction rate. Wherein t is the slice thickness and A is the infarct size.
2.5 serum IL-1 beta, TNF-alpha and MMP-9 expression level assays
The rats in each group are fasted before material taking, water is not forbidden for 12h, 10% chloral hydrate is anesthetized by intraperitoneal injection according to the weight of 0.35mL/100g of the rats, blood is taken from the abdominal aorta, the rats are kept still for 1h, centrifugation is carried out at 3500r/min at 4 ℃ for 10min, and supernatant liquid is sucked and placed in a centrifuge tube to be stored in a refrigerator at-80 ℃ for standby. The expression levels of IL-1 beta, TNF-alpha and MMP-9 in the serum of rats in each group are detected by an ELISA kit.
2.6 statistical treatment
Analyzing the experimental data by adopting E [ cel 2010 software; the data are expressed as x. + -. s, where P <0.05 indicates statistical significance. The uniform design uses a DPS data processing system to perform multiple regression analyses, and secondary multiple stepwise regression analysis is selected as the optimal analysis method.
3 results
Effect on rat neural function:
compared with a sham operation group, the rat nerve function score of the model group is obviously increased (P is less than 0.01), and the model preparation success is preliminarily judged; compared with the model group, the rats in the N1 and N3 groups have obviously reduced neurological function scores (P <0.01 and P <0.05) after 14d administration, and the invention is suggested to have the effect of improving neurological functions. The results are shown in Table 3
TABLE 3 comparison of neurological scores in groups of rats
Note: compared with the group of the pseudo-operation,##P<0.01; in comparison with the set of models,#P<0.05，##P<0.01。
effect on cerebral infarct volume in rats:
compared with a sham operation group, the cerebral infarction volume of the rat in the model group is obviously increased (P <0.01), and the success of model preparation is further inferred; compared with the model group, after 14d administration, the cerebral infarction volumes of rats in the N1-N5 groups are all obviously reduced (P is less than 0.01, P is less than 0.05), and the N1 group has the most obvious effect, which indicates that the invention can obviously reduce the cerebral infarction volumes and has certain treatment effect on the cerebral infarction. The results are shown in Table 4
TABLE 4 comparison of cerebral infarct volumes of rats in each group
Note: compared with the group of the pseudo-operation,##P<0.01; in comparison with the set of models,#P<0.05，##P<0.01。
effect on rat serum IL-1 β, TNF- α and MMP-9 expression levels:
compared with a sham operation group, the expression levels of IL-1 beta, TNF-alpha and MMP-9 in the serum of rats in the model group are obviously increased (P < 0.01); compared with the model group, after 14d administration, the expression levels of IL-1 beta, TNF-alpha and MMP-9 in the serum of rats in the N1, N2, N3 and N4 groups are obviously reduced (P <0.01, P <0.05), wherein the N1 group has the best effect, and the invention is suggested to have certain anti-inflammatory and angiogenesis promoting effects. The results are shown in Table 5
TABLE 5 expression levels of IL-1 beta, TNF-alpha and MMP-9 in rat sera of groups
Note: compared with the group of the pseudo-operation,#P<0.05，##P<0.01; in comparison with the set of models,#P<0.05，##P<0.01。
the research indicates that the invention can reduce the volume of cerebral infarction, reduce the expression level of IL-1 beta, TNF-alpha and MMP-9 in serum and obviously improve the nerve function. The invention has the functions of anti-inflammation, anti-thrombus and promoting angiogenesis. The optimum compatibility proportion of the astragalus, the red paeony root and the divaricate saposhnikovia root screened by secondary multi-item stepwise regression analysis under the item of a DPS data processing system is 10: 3: 2.
although embodiments of the present invention have been shown and described above, it is understood that the above embodiments are exemplary and should not be construed as limiting the present invention, and that variations, modifications, substitutions and alterations can be made to the above embodiments by those of ordinary skill in the art within the scope of the present invention.
Claims (5)
1. A traditional Chinese medicine composition for treating cerebral infarction is characterized by being prepared from the following components in parts by weight: the raw material medicines comprise 9-30 parts by weight of astragalus, 6-12 parts by weight of red peony root and 5-10 parts by weight of divaricate saposhnikovia root.
2. In order to achieve better treatment effect, the astragalus, the red paeony root and the divaricate saposhnikovia root are mixed according to the weight ratio of 10: 3: 2 is prepared by weight proportion.
3. The method for preparing the traditional Chinese medicine composition for treating cerebral infarction according to claim 1 or 2, wherein the method for preparing the traditional Chinese medicine composition for treating cerebral infarction comprises the following steps:
step one, mixing the traditional Chinese medicine raw materials (astragalus, red peony root and divaricate saposhnikovia root) and distilled water according to a weight ratio of 1: 6-12 mixing and soaking;
step two, decocting the soaked astragalus, red peony root and divaricate saposhnikovia root, boiling for 1-2 hours, filtering to obtain filter residues, adding water for mixing, boiling, and repeating for 2-3 times;
and step three, combining the filtrates obtained each time, concentrating by using a rotary evaporator, and drying under reduced pressure and vacuum to obtain the traditional Chinese medicine composition for treating cerebral infarction.
4. A traditional Chinese medicine oral preparation for treating cerebral infarction is characterized in that: which comprises the traditional Chinese medicine composition as claimed in claim 1 or 2 and pharmaceutically acceptable auxiliary materials.
5. The oral preparation for treating cerebral infarction according to claim 4, which is characterized by comprising oral liquid, tablets, capsules and pills, preferably capsules and tablets.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110242613.6A CN112843133A (en) | 2021-03-05 | 2021-03-05 | Traditional Chinese medicine composition for treating cerebral infarction and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110242613.6A CN112843133A (en) | 2021-03-05 | 2021-03-05 | Traditional Chinese medicine composition for treating cerebral infarction and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112843133A true CN112843133A (en) | 2021-05-28 |
Family
ID=75991808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110242613.6A Pending CN112843133A (en) | 2021-03-05 | 2021-03-05 | Traditional Chinese medicine composition for treating cerebral infarction and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112843133A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1853688A (en) * | 2005-04-25 | 2006-11-01 | 北京天力正元医药技术开发有限公司 | Chinese medicinal preparation for treating heart cerebrovascular disease and ischemic apoplexia and making method thereof |
| CN1903260A (en) * | 2005-07-29 | 2007-01-31 | 天津市石天药业有限责任公司 | Traditional Chinese medicine prepns. for treating ischemic cerebrovascular disease |
| CN101036705A (en) * | 2007-04-10 | 2007-09-19 | 邵旭 | Buyang huanwu gantong medicine for preventing and curing cardiovascular or cerebrovascular disease and the agent and the method for preparing the same |
| CN101732402A (en) * | 2010-01-27 | 2010-06-16 | 浙江中医药大学 | Medicament for preventing and treating ischemic brain injury, and preparation method thereof |
| CN104324135A (en) * | 2014-11-04 | 2015-02-04 | 湖南中医药大学 | Traditional Chinese medicine composition for treating ischemic stroke and preparation method and application of traditional Chinese medicine composition |
| CN109481501A (en) * | 2017-09-11 | 2019-03-19 | 李堃 | For treating the flax benevolence wine of apoplexy |
-
2021
- 2021-03-05 CN CN202110242613.6A patent/CN112843133A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1853688A (en) * | 2005-04-25 | 2006-11-01 | 北京天力正元医药技术开发有限公司 | Chinese medicinal preparation for treating heart cerebrovascular disease and ischemic apoplexia and making method thereof |
| CN1903260A (en) * | 2005-07-29 | 2007-01-31 | 天津市石天药业有限责任公司 | Traditional Chinese medicine prepns. for treating ischemic cerebrovascular disease |
| CN101036705A (en) * | 2007-04-10 | 2007-09-19 | 邵旭 | Buyang huanwu gantong medicine for preventing and curing cardiovascular or cerebrovascular disease and the agent and the method for preparing the same |
| CN101732402A (en) * | 2010-01-27 | 2010-06-16 | 浙江中医药大学 | Medicament for preventing and treating ischemic brain injury, and preparation method thereof |
| CN104324135A (en) * | 2014-11-04 | 2015-02-04 | 湖南中医药大学 | Traditional Chinese medicine composition for treating ischemic stroke and preparation method and application of traditional Chinese medicine composition |
| CN109481501A (en) * | 2017-09-11 | 2019-03-19 | 李堃 | For treating the flax benevolence wine of apoplexy |
Non-Patent Citations (1)
| Title |
|---|
| 常章富: "黄芪防风治中风", 《医药与保健》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104208302A (en) | Fructus rosae laevigatae healthy oral solution for reducing blood fat and preparation method thereof | |
| CN104958607A (en) | Traditional Chinese medicine composition for treating burning mouth syndromes of climacteric women and preparation method thereof | |
| CN115120689A (en) | Application of Xinli rehabilitation formula preparation in preparation of medicines | |
| CN106728387B (en) | Compound medicine with function of promoting immunity and preparation method thereof | |
| CN112402554B (en) | Traditional Chinese medicine composition for treating leukoencephalopathy and application thereof | |
| CN112843133A (en) | Traditional Chinese medicine composition for treating cerebral infarction and preparation method thereof | |
| CN108567914A (en) | It is a kind of that there is the Chinese medicine preparation and its preparation method and application for improving sleep effect | |
| CN103920058A (en) | Traditional Chinese medicine preparation for treating headache and preparation method thereof | |
| CN112704699A (en) | Traditional Chinese medicine composition for treating climacteric syndrome and application thereof | |
| CN102988747B (en) | Aristida triseta electuary for reducing hypertension, hyperglycemia and hyperlipidemia and preparation method thereof | |
| CN109718304A (en) | Improve the Chinese medicine composition of the microcirculation of human body cardio and vascular function and pre- preventing thrombosis | |
| CN109718305A (en) | Improve energy and blood of human body function and improves the Chinese medicine composition that resist oxygen lack delays senescence | |
| CN109045144A (en) | A kind of intervention navel patch and preparation method thereof suitable for deficiency of yang matter crowd | |
| CN114617939B (en) | Traditional Chinese medicine preparation for treating ischemic cerebral apoplexy | |
| CN108379515B (en) | Medicine with angina pectoris treating effect and preparation method thereof | |
| CN116999486B (en) | Zhuang medicine compound medicine for treating ischemic stroke convalescence and preparation method thereof | |
| CN108671149B (en) | Traditional Chinese medicine composition for treating liver diseases and preparation thereof | |
| CN105106855A (en) | Traditional Chinese medicine preparation for treating apoplexy sequela | |
| CN1281237C (en) | Radiation-proof frost-like powder for beauty white and dispelling speckle | |
| CN117717599A (en) | Traditional Chinese medicine composition for relieving physical fatigue and preparation method and application thereof | |
| CN114668800A (en) | Traditional Chinese medicine composition for treating female hyperplasia of mammary glands and preparation method and application thereof | |
| CN105343394A (en) | Traditional Chinese medicine composition for treating hypertension | |
| CN104887757B (en) | The Chinese medicine composition and massage cream of freeing vessels and nourishing heart | |
| CN115969950A (en) | Traditional Chinese medicine composition for preventing and treating diabetic peripheral neuropathy and preparation method thereof | |
| CN113288991A (en) | Traditional Chinese medicine cataplasm for treating hyperplasia of mammary glands with anxiety and depression and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210528 |